Related Experiment Video
Updated: Mar 15, 2026
Co-immunoprecipitation of the Mouse Mx1 Protein with the Influenza A Virus Nucleoprotein
Published on: April 21, 2015
Broad Spectrum Anti-Influenza Agents by Inhibiting Self-Association of Matrix Protein 1
Philip D Mosier1, Meng-Jung Chiang2, Zhengshi Lin2
1Department of Medicinal Chemistry and Institute for Structural Biology, Drug Discovery and Development, School of Pharmacy, Virginia Commonwealth University, Richmond, Virginia, United States of America.
Abstract:
The matrix protein 1 (M1) of influenza A virus (IAV) exists as a three-dimensional oligomeric structure in mature virions with high sequence conservation across different IAV subtypes, which makes it a potential broad spectrum antiviral target. We hypothesized that impairing self-association of M1 through a small molecule 'wedge', which avidly binds to an M1-M1 interface, would result in a completely new class of anti-influenza agents. To establish this proof-of-principle, we performed virtual screening on a library of >70,000 commercially available small molecules that resulted in several plausible 'wedges'. Biophysical studies showed that the best molecule bound the M1 protein potently and weakened M1-M1 self-association. Most importantly, the agent reduced the thickness of the M1 layer in mature virions and inhibited in ovo propagation of multiple IAV strains including H1N1, pandemic H1N1, H3N2 and H5N1, which supports the "wedge" hypothesis. These results demonstrate that M1 is a promising druggable target for the discovery of a completely new line of broad spectrum anti-IAV agents.
Insights
Researchers identified a novel small molecule that disrupts the matrix protein 1 (M1) self-association in influenza A virus (IAV). This discovery offers a new strategy for developing broad-spectrum antiviral agents against influenza.
Area of Science:
- Virology
- Drug Discovery
- Structural Biology
Background:
- Influenza A virus (IAV) matrix protein 1 (M1) forms a conserved oligomeric structure in virions.
- M1's conserved nature suggests it as a potential broad-spectrum antiviral target.
Purpose of the Study:
- To investigate if small molecules can impair M1 self-association, creating a new class of anti-influenza agents.
- To establish proof-of-principle for targeting the M1-M1 interface with small molecule 'wedges'.
Main Methods:
- Virtual screening of over 70,000 small molecules to identify potential M1-binding 'wedges'.
- Biophysical assays to confirm M1 protein binding and assess M1-M1 self-association.
- In ovo viral propagation assays using multiple IAV strains.
Main Results:
- Identified small molecules that bind M1 protein and weaken M1-M1 self-association.
- Demonstrated that the lead molecule reduces M1 layer thickness in mature virions.
- Showed inhibition of in ovo propagation for multiple IAV strains (H1N1, pandemic H1N1, H3N2, H5N1).
Conclusions:
- M1 protein is a druggable target for novel anti-IAV agents.
- Small molecule 'wedges' disrupting M1 self-association represent a new therapeutic strategy.
- This approach holds promise for developing broad-spectrum antivirals against influenza.
Related Concept Videos
02:28Leaky Scanning
01:23Antimicrobial Proteins
Interferons
Interferons (IFNs) are proteins produced by lymphocytes, macrophages, and fibroblasts infected with viruses. While IFNs cannot prevent viruses from entering and...